Overview

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Status:
Active, not recruiting

Trial end date:
2023-07-19

Target enrollment:

Participant gender:

Summary

A study in previously untreated Chronic Lymphocytic Leukemia participants to evaluate alternate administration strategies for induction therapy (debulking) with obinutuzumab or obinutuzumab/bendamustine prior to combination therapy with obinutuzumab and venetoclax.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Bendamustine Hydrochloride
Obinutuzumab
Venetoclax